LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

ALAMEDA, Calif.--(BUSINESS WIRE)--

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec) manufactured recombinant proteins related to stem cell research in its recently launched LifeMap BioReagents portal (http://bioreagents.lifemapsc.com) to researchers worldwide. ProSpecs innovative recombinant proteins, including growth factors, signaling molecules, differentiation factors, hormones, cytokines and chemokines will complement the current BioTime research product lines available via LifeMap BioReagents, including BioTimes PureStem human progenitor cell lines, PureStem packages, clinical and research grade human embryonic stem cell lines (hES), ESpan growth media for progenitor cell lines, and cell differentiation media.

The addition of ProSpec products reflects LifeMap Sciences execution of its strategy to market a growing catalog of research products to aid scientists in a variety of fields, including stem cell research, developmental biology, mechanisms of various human diseases and drug and therapeutic discovery.

LifeMap Sciences holds an exclusive, worldwide license to market GeneCards (www.genecards.org), the human gene compendium, and MalaCards (www.malacards.org), a database with nearly 17,000 human disease entries, from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. Additionally, it has recently launched version 1.1 of LifeMap Discovery, a comprehensive embryonic development and stem cell compendium, a database owned and developed by LifeMap Sciences. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views in the past 12 months. Links from LifeMap Discovery to BioTime and ProSpec manufactured products in the LifeMap BioReagents portal will enable researchers who access the database to become familiar with, and purchase, products that relate directly to the types of cells, genes or diseases that they are studying and can assist them in various research projects.

We are pleased to meet this significant milestone in our e-Commerce strategy, stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. Our growing LifeMap Discovery user base will now be able to identify high quality recombinant proteins that can be helpful for their research and purchase them via LifeMap BioReagents. This will increase LifeMap BioReagents brand awareness and the quality of our offering to the global biomedical research community.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem cell research. This platform includes GeneCards, the leading human gene database; LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap Sciences also markets PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTimes principal marketing subsidiary for research products, including PureStem human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its LifeMap BioReagents portal. LifeMap Sciences utilizes its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMaps scientists utilize LifeMaps proprietary platform, including LifeMap Discovery, its stem cell database along with the GeneCards and MalaCards integrated database suite, to aid in the development of BioTimes proprietary PureStem human progenitor cell lines into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. The LifeMap Discovery platform will be used to select the progenitor cell lines that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases.

About ProSpec-Tany TechnoGene Ltd.

Read the original here:
LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene